Sutro Biopharma Inc STRO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $23.57
- Day Range
- $22.58–24.05
- 52-Week Range
- $7.17–41.64
- Bid/Ask
- $22.88 / $23.01
- Shares Outstanding
- 16.57M
- Market Cap
- $375.49M
- Volume/Avg
- 71,833 / 347,789
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.29
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 133
- Website
- https://www.sutrobio.com
Valuation
|
Metric
|
STRO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 2.29 |
Price/Cash Flow | — |
Price/Earnings
STRO
Financial Strength
|
Metric
|
STRO
|
|---|---|
Quick Ratio | 3.04 |
Current Ratio | 3.12 |
Interest Coverage | −2.85 |
Quick Ratio
STRO
Profitability
|
Metric
|
STRO
|
|---|---|
Return on Assets (Normalized) | −45.97% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
STRO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|DgT^ZYS | LOCK|@JjL< | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%$v%fC | LOCK|&dd$w | $71B | |||
| argenx SE ADR
ARGX
| LOCK|Py^hg# | LOCK|ZY | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|pC$$?R | LOCK|mx@ | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|GN?Mdtr | LOCK|m$$zz | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>!T^hd!x | LOCK|d^svT | $26B | |||
| Moderna Inc
MRNA
| LOCK|dVFYlzM | LOCK|B#^ | $25B | |||
| Incyte Corp
INCY
| LOCK|^Tw?x!k | LOCK|%@% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Pn&?w!< | LOCK|^# | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|B!$c%qc | LOCK|@m | $16B |
United States